This website uses cookies. By using our site you agree to our privacy policy
Part One: Molecular Screening and Treatment in MDS, Mutant IDH as a Target, and Enasidenib
Part Two: Luspatercept in Lower Risk MDS: Updates from the PACE Study and Phase 2 Studies in Patients with Anemia